Vi­sion or voodoo? Biotech IPO mas­ter Vivek Ra­maswamy is still set­ting up new biotechs and hatch­ing more deals

In the 18 months since Vivek Ra­maswamy blind­sided the biotech in­dus­try with a record-set­ting IPO for the mys­tery biotech Ax­o­vant, the one-time hedge fund mae­stro turned drug en­tre­pre­neur has set up three more com­pa­nies and tak­en one of them pub­lic at near su­per­son­ic speed, all while busi­ly in-li­cens­ing drugs from a grow­ing list of sup­pli­ers.

And he isn’t slow­ing down. In a sit­down with me at JP Mor­gan this week, Ra­maswamy says he may well un­cork an­oth­er start­up and strike up an­oth­er three or four deals in 2017.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER